Kombinált cisplatin-tartalmú kemoterápia randomizált vizsgálata a fej-nyak régióban lévó planocellularis rákok kezelésében.

Translated title of the contribution: Randomized study of cisplatin-based combination chemotherapy for the treatment of planocellular cancer of the head and neck region

L. Olasz, A. Németh, Z. Nyárády, T. Tornóczky, L. Királyfalvi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Between January 1996 and November 1998 38 patients were treated with induction chemotherapy. Patients were distributed in two randomized groups, 19-19 patients in each, receiving (group N) either bleomycin, vincristine and methotrexate (BVM) or the previous medication plus cisplatin (BVCM) chemotherapy (group C). Side effects were low and reversible during the treatments. The clinical regression rate (RR) of the cases was 87% including complete regression 24%. There was no difference between the two groups. There was no difference in the pathological macroscopic regression, however group C was better in microscopic regression. During the 27.5 months of average follow-up time, group N had a significantly better result in the tumor-free survival, with a lower rate of metastatic recidives (N/C = 2/9). There was no significant difference in the overall survival rate, due to the radical neck dissections of recidive metastases. According to our experience we recommend the use of cisplatin in conjunction with neck radiotherapy.

Original languageHungarian
Pages (from-to)2433-2437
Number of pages5
JournalOrvosi Hetilap
Volume141
Issue number45
Publication statusPublished - Nov 5 2000

Fingerprint

Head and Neck Neoplasms
Combination Drug Therapy
Cisplatin
Induction Chemotherapy
Neck Dissection
Bleomycin
Vincristine
Methotrexate
Neck
Radiotherapy
Therapeutics
Survival Rate
Neoplasm Metastasis
Drug Therapy
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kombinált cisplatin-tartalmú kemoterápia randomizált vizsgálata a fej-nyak régióban lévó planocellularis rákok kezelésében. / Olasz, L.; Németh, A.; Nyárády, Z.; Tornóczky, T.; Királyfalvi, L.

In: Orvosi Hetilap, Vol. 141, No. 45, 05.11.2000, p. 2433-2437.

Research output: Contribution to journalArticle

@article{e565133603fc4a25aa0dea1e4f4a214e,
title = "Kombin{\'a}lt cisplatin-tartalm{\'u} kemoter{\'a}pia randomiz{\'a}lt vizsg{\'a}lata a fej-nyak r{\'e}gi{\'o}ban l{\'e}v{\'o} planocellularis r{\'a}kok kezel{\'e}s{\'e}ben.",
abstract = "Between January 1996 and November 1998 38 patients were treated with induction chemotherapy. Patients were distributed in two randomized groups, 19-19 patients in each, receiving (group N) either bleomycin, vincristine and methotrexate (BVM) or the previous medication plus cisplatin (BVCM) chemotherapy (group C). Side effects were low and reversible during the treatments. The clinical regression rate (RR) of the cases was 87{\%} including complete regression 24{\%}. There was no difference between the two groups. There was no difference in the pathological macroscopic regression, however group C was better in microscopic regression. During the 27.5 months of average follow-up time, group N had a significantly better result in the tumor-free survival, with a lower rate of metastatic recidives (N/C = 2/9). There was no significant difference in the overall survival rate, due to the radical neck dissections of recidive metastases. According to our experience we recommend the use of cisplatin in conjunction with neck radiotherapy.",
author = "L. Olasz and A. N{\'e}meth and Z. Ny{\'a}r{\'a}dy and T. Torn{\'o}czky and L. Kir{\'a}lyfalvi",
year = "2000",
month = "11",
day = "5",
language = "Hungarian",
volume = "141",
pages = "2433--2437",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "45",

}

TY - JOUR

T1 - Kombinált cisplatin-tartalmú kemoterápia randomizált vizsgálata a fej-nyak régióban lévó planocellularis rákok kezelésében.

AU - Olasz, L.

AU - Németh, A.

AU - Nyárády, Z.

AU - Tornóczky, T.

AU - Királyfalvi, L.

PY - 2000/11/5

Y1 - 2000/11/5

N2 - Between January 1996 and November 1998 38 patients were treated with induction chemotherapy. Patients were distributed in two randomized groups, 19-19 patients in each, receiving (group N) either bleomycin, vincristine and methotrexate (BVM) or the previous medication plus cisplatin (BVCM) chemotherapy (group C). Side effects were low and reversible during the treatments. The clinical regression rate (RR) of the cases was 87% including complete regression 24%. There was no difference between the two groups. There was no difference in the pathological macroscopic regression, however group C was better in microscopic regression. During the 27.5 months of average follow-up time, group N had a significantly better result in the tumor-free survival, with a lower rate of metastatic recidives (N/C = 2/9). There was no significant difference in the overall survival rate, due to the radical neck dissections of recidive metastases. According to our experience we recommend the use of cisplatin in conjunction with neck radiotherapy.

AB - Between January 1996 and November 1998 38 patients were treated with induction chemotherapy. Patients were distributed in two randomized groups, 19-19 patients in each, receiving (group N) either bleomycin, vincristine and methotrexate (BVM) or the previous medication plus cisplatin (BVCM) chemotherapy (group C). Side effects were low and reversible during the treatments. The clinical regression rate (RR) of the cases was 87% including complete regression 24%. There was no difference between the two groups. There was no difference in the pathological macroscopic regression, however group C was better in microscopic regression. During the 27.5 months of average follow-up time, group N had a significantly better result in the tumor-free survival, with a lower rate of metastatic recidives (N/C = 2/9). There was no significant difference in the overall survival rate, due to the radical neck dissections of recidive metastases. According to our experience we recommend the use of cisplatin in conjunction with neck radiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0034610145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034610145&partnerID=8YFLogxK

M3 - Article

VL - 141

SP - 2433

EP - 2437

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 45

ER -